We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Puretech Health plc (PRTC) Ordinary 1p

Sell:211.50p Buy:213.50p 0 Change: No change
FTSE 250:0.41%
Market closed Prices as at close on 24 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:211.50p
Buy:213.50p
Change: No change
Market closed Prices as at close on 24 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:211.50p
Buy:213.50p
Change: No change
Market closed Prices as at close on 24 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.

Contact details

Address:
6 Tide Street, Suite 400
BOSTON
02210
United States
Telephone:
+1 (0617) 4822333
Website:
https://puretechhealth.com/

Important dates

Future events
There are no future events available.
Past events
Final results 25 April 2024 25/04/24
Annual report 25 April 2024 25/04/24
Trading Announcement 20 December 2023 20/12/23
Interim results 29 August 2023 29/08/23
AGM 13 June 2023 13/06/23
Final results 28 April 2023 28/04/23

General stock information

EPIC:
PRTC
ISIN:
GB00BY2Z0H74
Market cap:
£573.64 million
Shares in issue:
269.95 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE 250,FTSE 350,FTSE All Share

Key personnel

  • Eric Elenko
    President, Director
  • Bharatt Chowrira
    Chief Executive Officer, Director
  • Robert Langer
    Co-Founder, Non-Executive Director
  • Julie Krop
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.